MSD, known as Merck & Co. in the US, says lack of UK investment in life sciences and undervaluation of innovative medicines drove decision to cancel flagship King’s Cross Discovery Centre.

Merck & Co., Inc. has scrapped plans to build a £1bn research hub in London and is cutting 125 science jobs, a move that signals wider challenges for the UK’s ambition to remain a global life sciences leader.

An MSD spokesperson said the decision “follows an evaluation of our company’s global discovery research capabilities as part of our multiyear optimization and reflects the challenges of the UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successive UK Governments.”

The move marks the end of what had been one of the most high-profile projects in the UK research pipeline, with the proposed facility expected to open in 2027 as a flagship site for pharmaceutical innovation.

The planned UK Discovery Centre, at Belgrove House in King’s Cross, was set to employ around 800 people, including almost 200 scientists. Positioned opposite St Pancras station, the building was designed to stand as a highly visible symbol of investment in UK science. Its cancellation is now a major setback for the country’s research and innovation landscape, reducing both future capacity and confidence.

Instead of creating a new base in London, Merck will consolidate research activities at its existing international sites, with much of the work expected to shift to the United States. While the company will retain other operations in the UK, including its animal health facility in Milton Keynes, the absence of the Discovery Centre represents a loss of prestige and momentum.

The spokesperson added that MSD “intends to vacate laboratories occupied at the London Bioscience Innovation Centre (LBIC) and the Francis Crick Institute by the end of 2025, impacting approximately 125 positions,” while stressing that “MSD continues discovery research at other sites in its research and development network.”

The decision has shone a spotlight on wider pressures within the UK life sciences sector. Despite a strong academic base and historic strengths in research, industry leaders have raised concerns about the country’s competitiveness compared with other global hubs. Complex regulation, drug pricing constraints, and fewer incentives for early-stage discovery are often cited as barriers that limit new investment.

This loss comes at a time when the UK is working to establish itself as a global science and technology powerhouse by 2030. In recent years, however, foreign investment in R&D has slowed, and the country has slipped down international rankings for industry-sponsored trials. Companies evaluating where to base long-term research increasingly weigh cost, speed of development, and regulatory clarity. Against that backdrop, Merck’s decision underscores the difficulty of retaining major global projects.

The impact of the cancellation will be felt most keenly in London, where the Discovery Centre had been expected to provide high-value employment and foster collaboration across academia, industry, and start-ups. Beyond the immediate job losses, the withdrawal of such a large-scale project risks creating uncertainty about future investment in the capital’s life sciences cluster.

At a strategic level, the move may also alter the UK’s positioning in the global innovation race. Other regions, particularly in Europe, North America, and Asia, are investing heavily in infrastructure and offering targeted incentives to attract discovery research. Unless the UK strengthens its offer, analysts suggest further projects may migrate elsewhere.

Despite these concerns, Merck continues to maintain a significant presence in the UK through existing sites and commercial operations. The company’s medicines remain widely available, and it continues to collaborate with healthcare partners across the NHS and academia. Nevertheless, the cancelled project highlights the fine balance between retaining current investment and attracting the next wave of global research activity.

The UK government has consistently stated its intention to grow life sciences as a strategic priority sector, citing its role in economic growth, high-skilled employment, and resilience in the face of global health challenges. Whether policy adjustments can restore momentum and rebuild industry confidence remains to be seen.

Merck’s withdrawal of the Discovery Centre stands as a clear signal of the competitive pressures the UK faces in attracting long-term pharmaceutical research. Without decisive action, the country risks losing ground in a rapidly shifting global market that rewards speed, innovation, and supportive policy environments.